Uni­ty finds it­self with a fi­nite amount of cash as new da­ta pro­vide a ray of hope for in­vestors

It has not been an easy road for the an­ti-ag­ing start­up Uni­ty Biotech­nol­o­gy. From staff cuts to a lead pro­gram loss, the com­pa­ny has run in­to sev­er­al ob­sta­cles on its jour­ney, but their lat­est news points to both the per­ils and po­ten­tial ahead.

In the biotech’s Q2 re­sults on Fri­day, the com­pa­ny re­vealed it has on­ly enough cash to fund its op­er­a­tions through the first quar­ter of next year, with post­ed re­sults show­ing that Uni­ty had $64.5 mil­lion in cash and mar­ket se­cu­ri­ties at the end of the quar­ter. This is com­pared to the $79.2 mil­lion the biotech had at the end of March. The com­pa­ny al­so had an op­er­at­ing loss of $12.3 mil­lion for the quar­ter as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER